WGU D027 Objective Assessment Final Exam
2025/2026 | Verified Questions & dDetailed Answers |
A+ Verified
Which of the following statements is correct regarding
insulin glargine?
A. It is primarily used to control postprandial
hyperglycemia.
B. It is a "peakless" insulin.
C. The prolonged duration of activity is due to slow
dissociation from albumin.
D. It should not be used in a regimen with insulin lispro or
glulisine - ANSWER-Correct answer = B. Insulin glargine
has a relatively flat, prolonged hypoglycemic effect.
Because of this it is used for basal glucose control, not
postprandial. The prolonged duration is due to its low pH,
,which leads to precipitation at the injection site and
resultant extended action. Insulin glargine is often used for
basal control in a regimen where insulin lispro, glulisine, or
aspart are used for mealtime glucose control. [Note:
Glargine should not be combined with other insulins in the
same syringe, as it may alter the pharmacodynamic
properties of the medication.]
MC is a patient with type 2 diabetes currently being
treated with insulin detemir. The physician determines that
MC needs additional insulin therapy for control of
postprandial glucose. Which agent is most appropriate to
add at this time?
A. Insulin degludec
B. NPH insulin
,C. Insulin lispro
D. NPH/regular 70/30 insulin - ANSWER-Correct answer =
C. Insulin lispro is a rapid-acting insulin that has an onset
of action within 15 to 30 minutes. Rapid-acting insulins are
administered to mimic the prandial (mealtime) release of
insulin and control postprandial glucose levels. Insulin
degludec is a long-acting insulin used to control fasting
glucose levels. NPH insulin is an intermediate-acting
insulin also used for basal (fasting) control. NPH/regular
70/30 insulin is a mixture of NPH (intermediateacting) and
regular (short-acting) insulin. The patient is already on a
long-acting insulin (detemir) for basal control, and another
insulin for basal control is not warranted.
, Which class of oral diabetes drugs is paired most
appropriately with its primary mechanism of action?
A. DPP-4 inhibitor—inhibits breakdown of complex
carbohydrates
B. SGLT2 inhibitor—increases urinary excretion of glucose
C. Sulfonylurea—increases insulin sensitivity
D. Thiazolidinedione—decreases hepatic gluconeogenesis
- ANSWER-Correct answer = B. SGLT2 inhibitors work by
inhibiting the sodium-glucose cotransporter 2 (SGLT2),
resulting in decreased reabsorption of glucose in the
kidney and increased urinary excretion. Sulfonylureas
work primarily by increasing insulin secretion through
stimulation of the β cells in the pancreas. DPP-4 inhibitors
work by inhibiting breakdown of incretins, thereby
increasing postprandial insulin secretion, decreasing
2025/2026 | Verified Questions & dDetailed Answers |
A+ Verified
Which of the following statements is correct regarding
insulin glargine?
A. It is primarily used to control postprandial
hyperglycemia.
B. It is a "peakless" insulin.
C. The prolonged duration of activity is due to slow
dissociation from albumin.
D. It should not be used in a regimen with insulin lispro or
glulisine - ANSWER-Correct answer = B. Insulin glargine
has a relatively flat, prolonged hypoglycemic effect.
Because of this it is used for basal glucose control, not
postprandial. The prolonged duration is due to its low pH,
,which leads to precipitation at the injection site and
resultant extended action. Insulin glargine is often used for
basal control in a regimen where insulin lispro, glulisine, or
aspart are used for mealtime glucose control. [Note:
Glargine should not be combined with other insulins in the
same syringe, as it may alter the pharmacodynamic
properties of the medication.]
MC is a patient with type 2 diabetes currently being
treated with insulin detemir. The physician determines that
MC needs additional insulin therapy for control of
postprandial glucose. Which agent is most appropriate to
add at this time?
A. Insulin degludec
B. NPH insulin
,C. Insulin lispro
D. NPH/regular 70/30 insulin - ANSWER-Correct answer =
C. Insulin lispro is a rapid-acting insulin that has an onset
of action within 15 to 30 minutes. Rapid-acting insulins are
administered to mimic the prandial (mealtime) release of
insulin and control postprandial glucose levels. Insulin
degludec is a long-acting insulin used to control fasting
glucose levels. NPH insulin is an intermediate-acting
insulin also used for basal (fasting) control. NPH/regular
70/30 insulin is a mixture of NPH (intermediateacting) and
regular (short-acting) insulin. The patient is already on a
long-acting insulin (detemir) for basal control, and another
insulin for basal control is not warranted.
, Which class of oral diabetes drugs is paired most
appropriately with its primary mechanism of action?
A. DPP-4 inhibitor—inhibits breakdown of complex
carbohydrates
B. SGLT2 inhibitor—increases urinary excretion of glucose
C. Sulfonylurea—increases insulin sensitivity
D. Thiazolidinedione—decreases hepatic gluconeogenesis
- ANSWER-Correct answer = B. SGLT2 inhibitors work by
inhibiting the sodium-glucose cotransporter 2 (SGLT2),
resulting in decreased reabsorption of glucose in the
kidney and increased urinary excretion. Sulfonylureas
work primarily by increasing insulin secretion through
stimulation of the β cells in the pancreas. DPP-4 inhibitors
work by inhibiting breakdown of incretins, thereby
increasing postprandial insulin secretion, decreasing
